EP0350990B1 - Pyridazinone derivatives - Google Patents
Pyridazinone derivatives Download PDFInfo
- Publication number
- EP0350990B1 EP0350990B1 EP89201716A EP89201716A EP0350990B1 EP 0350990 B1 EP0350990 B1 EP 0350990B1 EP 89201716 A EP89201716 A EP 89201716A EP 89201716 A EP89201716 A EP 89201716A EP 0350990 B1 EP0350990 B1 EP 0350990B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- benzo
- thien
- methyl
- pyridazinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 *C(CC(O)=O)C(C1NC(CCCC2)C2C1*)=O Chemical compound *C(CC(O)=O)C(C1NC(CCCC2)C2C1*)=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the invention relates to pyridazinone compounds of the general formula I: wherein R1 represents one to four substituents, which may be the same or different and are selected from OH, unsubstituted or C1-C4 alkyl substituted amino, C1-C4 halogen substituted alkyl,O-ALK-NR4R5, C1-C4 alkoxy, whereby two substituents taken together may also represent a methylenedioxy group ; R2 and R3 represent independently H or C1-C4 alkyl; R4 and R5 represent independently H or C1-C4 alkyl, or form together with the nitrogen a 5- or 6-membered ring, ALK represents a branched or unbranched alkylene group with 2-6 C atoms, which optionally may be substituted with hydroxy or halogen; X represents S or O; the dotted line represents an optional bond; and their pharmaceutically acceptable salts.
- R1 represents one to four substituents, which may be the same or different and are
- the compounds according to the invention have a cardiotonic, blood platelet aggregation inhibiting, systemic vasodilator, pulmonary vasodilator, and bronchodilator activity, and more particularly they show a very potent increase of the force of the muscular contractions of the heart, reduce afterload on the heart, improve pulmonary blood flow, and improve airways ventilation, which may be mediated by phosphodiesterase inhibition, and among others can be used for treating heart failure and asthma.
- thiadiazinone, oxadiazinone or triazinone heterocyclic compounds which differ in that the methylene group at the 4-position of the pyridazinone ring is replaced by -S-, -O-, or -NR-, which lack additional substituents at the phenyl moiety, and which pyridazinone-like moiety is substituted at the 3-position of the benzo[b]thienyl group, are described in European Patent Application 0085227.
- Preferred compounds have 2, 3 or 4 substituents R1, selected from OH, C1-C4 alkoxy or O-ALK-NR4R5, and R2 and R3 represent H or CH3.
- R1 represents 2 or 3 substituents selected from OH, OCH3, OC2H5, 2-(piperidin-1-yl)ethyloxy or 2-(piperidin-1-yl)propyloxy
- R2 represents H
- R3 represents CH3
- X represents S
- the optional bond is not present, and in particular compound II
- the 5- or 6-ring formed by R4 and R5 together with the nitrogen atom may have an additional oxygen or nitrogen atom, may be saturated or unsaturated, and may be substituted with C1-C4 alkyl.
- O-ALK-NR4R5 groups are 2-aminoethyloxy, 3-(methylamino)-propyloxy, 2-(dimethylamino)-ethyloxy, 2-(piperidin-1-yl)ethyloxy, 3-(piperidin-1-yl)propyloxy, 2-(piperazin-1-yl)ethyloxy, 2-(4-methylpiperazin-1-yl)ethyloxy, 3-(morpholin-1-yl)propyloxy, 2-methyl-3-(piperidin-1-yl)propyloxy, 2-hydroxy-3-(piperidin-1-yl)propyloxy, 2-(imidazol-1-yl)ethyloxy, and the like.
- salts are acid addition salts derived from acids, such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, maleic acid, fumaric acid, malonic acid, succinic acid, tartaric acid, lactic acid, citric acid, ascorbic acid, salicylic acid, benzoic acid and methanesulphonic acid, and the like.
- acids such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, maleic acid, fumaric acid, malonic acid, succinic acid, tartaric acid, lactic acid, citric acid, ascorbic acid, salicylic acid, benzoic acid and methanesulphonic acid, and the like.
- the compounds of this invention may be prepared by any method known for the preparation of analogous compounds.
- a suitable method of preparation of compounds according to general formula I is condensation of a ketoacid of formula III wherein R1, R2, R3, X and the dotted line have the aforesaid meanings or its alkyl (C1-C8) ester or carboxylic acid salt thereof with hydrazine, and preferably with hydrazine hydrate.
- This condensation is preferably performed in a suitable solvent like dioxan, ethanol, methanol, dimethylformamide and the like, or mixtures thereof.
- the reaction temperature is preferably between room temperature and reflux temperature of the solvent used.
- Oxidation may be performed by standard procedures.
- Well-known oxidation reagents include DDQ, CrO3, KMnO4, MnO2 or air in the presence of a suitable catalyst like Pt or Pd, and the like.
- the carboxylic acid salt of a compound of formula III is derived from a base, preferably comprising an alkali or earth-alkali metal, including Na, K, Ca and Mg.
- alkyl (C1-C8) ester represents esters derived from an aliphatic alkylalcohol with 1 to 8 carbon atoms, of which the alkyl group may be methyl, ethyl, propyl, butyl, sec-butyl, octyl, and the like.
- Keto acid III can be prepared by various routes, known for the preparation of analogous compounds.
- For the preparation of keto acid III reference is made to the flow sheet and the actual examples.
- R1 substituents R1 can easily be cleaved, after which the compound obtained may be used as such or brought into reaction with suitable reagents according to methods known per se. If R1, for instance, represents an alkoxy group, this group may be cleaved by known methods, e.g. by strong Lewis acids like boron tribromide, to give compounds according to this invention with R1 is hydroxy.
- R1 is alkoxy or NR4R5 substituted alkoxy, e.g. by reaction with an NR4R5 substituted or unsubstituted alkyl group, which is provided with a suitable leaving group, such as the p-toluenesulphonate group or a halogen.
- the compounds of formula I may -if appropriate- be isolated from the reaction mixture in the form of a pharmaceutically acceptable salt.
- the pharmaceutically acceptable salts may also be obtained by treating the free base of formula I with an organic or inorganic acid such as HCl, HBr, HI, H2SO4, H3PO4, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid, etc.
- Compounds according to this invention can be administered either orally, locally or parenterally, in a daily dose between 0.01 and 50 mg/kg body weight, and preferably between 0.1 and 10 mg/kg body weight.
- a daily dose between 5 and 500 mg is preferred.
- the compounds are processed in a form suitable for oral, local or parenteral administration, for example a tablet, pill, capsule, solution, emulsion, paste or spray.
- the oral form is the most preferred form of administration.
- Example 2 In an analogous manner as described in Example 1 were prepared: 4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl) -5-methyl-3(2H)-pyridazinone. m.p. 195-197 °C. 4,5-Dihydro-6-(6-methoxy-benzo ⁇ b ⁇ thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 210-212 °C. 4,5-Dihydro-6-(5-hydroxy-6-methoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. >275 °C.
- Example 3 In an analogous manner as described in Example 3 were prepared: 4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl)-3(2H)-pyridazinone. m.p. 188-190 °C.
- Example 6 In an analogous manner as described in Example 6 was prepared: 4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 195-197 °C.
- Example 8 In an analogous manner as described in Example 8 was prepared: 4,5-dihydro-6-(6-hydroxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 263-265 °C.
- Example 9 In an analogous manner as described in Example 9 were prepared: 4,5-Dihydro-6-(6-ethoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 236-239 °C. 4,5-Dihydro-6-(5-ethoxy-6-methoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 185-188 °C.
- Example 12 In an analogous manner as described in Example 12, were prepared: 4,5-Dihydro-6-(6-methoxy-5-[2-(piperidin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride. m.p. 192-200 °C 4,5-Dihydro-6-(5-[2-(piperidin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride. m.p.
- 4,5-Dihydro-6-(6-methoxy-5-[2-hydroxy-3-(piperidin-1-yl)propyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride 4,5-Dihydro-6-(6-methoxy-5-[2-(4-methyl-piperazin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
- 4,5-Dihydro-6-(6-methoxy-5-[2-(piperazin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride 4,5-Dihydro-6-(6-methoxy-5-[2-(morpholin-4-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
- 4,5-Dihydro-6-(6-methoxy-5-[2-(piperidin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride 4,5-Dihydro-6-(5-[2-diethylaminoethyloxy]-6-methoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
Abstract
Description
- The invention relates to pyridazinone compounds of the general formula I:
wherein
R¹ represents one to four substituents, which may be the same or different and are selected from OH, unsubstituted or C1-C4 alkyl substituted amino, C1-C4 halogen substituted alkyl,O-ALK-NR⁴R⁵, C1-C4 alkoxy, whereby two substituents taken together may also represent a methylenedioxy group ;
R² and R³ represent independently H or C1-C4 alkyl;
R⁴ and R⁵ represent independently H or C1-C4 alkyl, or form together with the nitrogen a 5- or 6-membered ring,
ALK represents a branched or unbranched alkylene group with 2-6 C atoms, which optionally may be substituted with hydroxy or halogen;
X represents S or O;
the dotted line represents an optional bond; and their pharmaceutically acceptable salts. - The compounds according to the invention have a cardiotonic, blood platelet aggregation inhibiting, systemic vasodilator, pulmonary vasodilator, and bronchodilator activity, and more particularly they show a very potent increase of the force of the muscular contractions of the heart, reduce afterload on the heart, improve pulmonary blood flow, and improve airways ventilation, which may be mediated by phosphodiesterase inhibition, and among others can be used for treating heart failure and asthma.
- Pyridazinone derivatives with cardiovascular activities having other substituents at the 6-position are known from European Patent Applications 0008391 and 00071102, and DDR Patent DD 248362.
- Related thiadiazinone, oxadiazinone or triazinone heterocyclic compounds, which differ in that the methylene group at the 4-position of the pyridazinone ring is replaced by -S-, -O-, or -NR-, which lack additional substituents at the phenyl moiety, and which pyridazinone-like moiety is substituted at the 3-position of the benzo[b]thienyl group, are described in European Patent Application 0085227.
- Preferred compounds have 2, 3 or 4 substituents R¹, selected from OH, C1-C4 alkoxy or O-ALK-NR⁴R⁵, and R² and R³ represent H or CH₃.
-
- The 5- or 6-ring formed by R⁴ and R⁵ together with the nitrogen atom, may have an additional oxygen or nitrogen atom, may be saturated or unsaturated, and may be substituted with C1-C4 alkyl. Examples of O-ALK-NR⁴R⁵ groups are 2-aminoethyloxy, 3-(methylamino)-propyloxy, 2-(dimethylamino)-ethyloxy, 2-(piperidin-1-yl)ethyloxy, 3-(piperidin-1-yl)propyloxy, 2-(piperazin-1-yl)ethyloxy, 2-(4-methylpiperazin-1-yl)ethyloxy, 3-(morpholin-1-yl)propyloxy, 2-methyl-3-(piperidin-1-yl)propyloxy, 2-hydroxy-3-(piperidin-1-yl)propyloxy, 2-(imidazol-1-yl)ethyloxy, and the like.
- Pharmaceutically acceptable salts are acid addition salts derived from acids, such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, maleic acid, fumaric acid, malonic acid, succinic acid, tartaric acid, lactic acid, citric acid, ascorbic acid, salicylic acid, benzoic acid and methanesulphonic acid, and the like.
- The compounds of this invention may be prepared by any method known for the preparation of analogous compounds.
- A suitable method of preparation of compounds according to general formula I is condensation of a ketoacid of formula III
wherein R¹, R², R³, X and the dotted line have the aforesaid meanings or its alkyl (C1-C8) ester or carboxylic acid salt thereof with hydrazine, and preferably with hydrazine hydrate. - This condensation is preferably performed in a suitable solvent like dioxan, ethanol, methanol, dimethylformamide and the like, or mixtures thereof. The reaction temperature is preferably between room temperature and reflux temperature of the solvent used.
- The product obtained in the above mentioned process is subsequently oxidized if the dotted line of formula I represents a bond, and this bond is not present in keto acid III.
- Oxidation may be performed by standard procedures. Well-known oxidation reagents include DDQ, CrO₃, KMnO₄, MnO₂ or air in the presence of a suitable catalyst like Pt or Pd, and the like.
- The carboxylic acid salt of a compound of formula III is derived from a base, preferably comprising an alkali or earth-alkali metal, including Na, K, Ca and Mg. The term alkyl (C1-C8) ester, represents esters derived from an aliphatic alkylalcohol with 1 to 8 carbon atoms, of which the alkyl group may be methyl, ethyl, propyl, butyl, sec-butyl, octyl, and the like.
- Keto acid III can be prepared by various routes, known for the preparation of analogous compounds. For the preparation of keto acid III reference is made to the flow sheet and the actual examples.
- Compounds of general formula I may be converted into other compounds of general formula I. For instance, some substituents R¹ can easily be cleaved, after which the compound obtained may be used as such or brought into reaction with suitable reagents according to methods known per se. If R¹, for instance, represents an alkoxy group, this group may be cleaved by known methods, e.g. by strong Lewis acids like boron tribromide, to give compounds according to this invention with R¹ is hydroxy. Compounds of the general formula I with R¹ is hydroxy may be converted into compounds with R¹ is alkoxy or NR⁴R⁵ substituted alkoxy, e.g. by reaction with an NR⁴R⁵ substituted or unsubstituted alkyl group, which is provided with a suitable leaving group, such as the p-toluenesulphonate group or a halogen.
- This method is particularly useful for the preparation of compounds of general formula I wherein R¹ is O-ALK-NR⁴R⁵.
- The compounds of formula I may -if appropriate- be isolated from the reaction mixture in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salts may also be obtained by treating the free base of formula I with an organic or inorganic acid such as HCl, HBr, HI, H₂SO₄, H₃PO₄, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid, etc.
- When compounds of the general formula I contain chiral atoms the enantiomers, as well as mixtures thereof including the racemic mixture, belong to the invention. Pure enantiomers can be obtained by stereoselective synthesis or by resolution of the enantiomers of the end product or precursors thereof.
- Compounds according to this invention can be administered either orally, locally or parenterally, in a daily dose between 0.01 and 50 mg/kg body weight, and preferably between 0.1 and 10 mg/kg body weight. For human use a daily dose between 5 and 500 mg is preferred. For this purpose the compounds are processed in a form suitable for oral, local or parenteral administration, for example a tablet, pill, capsule, solution, emulsion, paste or spray. The oral form is the most preferred form of administration.
- The following examples further illustrate the preparation of the compounds used in this invention.
-
- a) 2-(5,6-Dimethoxy-benzo[b]thien-2-yl)-2-(4-morpholinyl) acetonitrile.
Morpholine (10.8 ml) was added to a stirred suspension of 5,6-dimethoxy-benzo[b]thiophene-2-carboxaldehyde (5.0 g) and p-toluenesulphonic acid monohydrate (4.3 g) in dry dioxan (43 ml) under an atmosphere of nitrogen. The mixture was heated at reflux for 30 min. and then the resultant solution was cooled to 50 °C and treated in one portion with a suspension of potassium cyanide (1.46 g) in water (2.5 ml). The reaction mixture was heated at reflux for 1 hour then cooled to room temperature and treated with 15% w/v potassium carbonate in water (20 ml). The reaction mixture was then diluted with water (200 ml) and the resultant precipitate was filtered and dried to give 2-(5,6-dimethoxy-benzo[b]thien-2-yl)-2-(4-morpholinyl)acetonitrile as a pale yellow solid (6.54 g). A portion crystallized from dichloromethane/diethyl ether had m.p. 196-199 °C. - b) 2-(5,6-Dimethoxy-benzo[b]thien-2-yl)-3-methyl-2-(4-morpholinyl) pentane dinitrile.
A suspension of 2-(5,6-dimethoxy-benzo[b]thiophene-2-yl)-2-(4-morpholinyl) acetonitrile in dry distilled tetrahydrofuran (70 ml) under an atmosphere of nitrogen was treated with 30% w/v potassium hydroxide in methanol (0.32 ml). A solution of crotononitrile (3.4 ml) in dry distilled tetrahydrofuran (5 ml) was then added dropwise over 10 min. After 45 min. the black solution was evaporated to dryness and the residual oil was treated with ice cold water (50 ml), the mixture was stirred, and the resultant solid was filtered and dried at 60 °C under vacuum to give 2-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-methyl-2-(4-morpholinyl)pentane dinitrile as an off-white solid (7.69 g). A portion crystallized from dichloromethane/diethyl ether had m.p. 162-165 °C. - c) 4-(5,6-Dimethoxy-benzo[b]thien-2-yl)-3-methyl-4-oxo-butane nitrile.
A mixture of 2-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-methyl-2-(4-morpholinyl)-pentanedinitrile (7.4 g), glacial acetic acid (37.5 ml) and water (12.5 ml) was stirred and heated at reflux under an atmosphere of nitrogen. After 45 min. the reaction mixture was cooled and poured into crushed ice (200 g). The ice was allowed to melt and the resultant precipitate was filtered and dried at 65 °C under vacuum to give 4-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-methyl-4-oxo-butane nitrile as a pale yellow solid (5.2 g). A portion crystallized from dichloromethane/diethyl ether had m.p. 148-150 °C. - d) 4-(5,6-Dimethoxy-benzo[b]thien-2-yl)-3-methyl-4-oxo-butanoic acid.
A mixture of 4-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-methyl-4-oxo-butane nitrile (4.0 g), 1-propanol (30 ml) and 5M hydrochloric acid (28 ml) was stirred and heated at reflux for 24 hours under an atmosphere of nitrogen. The reaction mixture was cooled, diluted with water (120 ml) and the product was then extracted into ethyl acetate (2 x 50 ml). The organic extracts were combined, washed with water (2 x 20 ml), dried (MgSO₄), filtered, and then evaporated to give a mixture of 4-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-methyl-4-oxo-butanoic acid and the corresponding propanoate ester as an oil (5.3 g). This mixture was dissolved in methanol (50 ml), then water (10 ml) and potassium carbonate (5.3 g) were added and the reaction mixture was stirred and heated at reflux. After 1 hour the solution was concentrated under reduced pressure then diluted with water (100 ml) and extracted with diethyl ether (2 x 30 ml). The aqueous layer was acidified with 5M hydrochloric acid and extracted with ethyl acetate (2 x 50 ml). The ethyl acetate extracts were combined, washed with water, dried (MgSO₄), filtered and evaporated to dryness to give 4-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-methyl-4-oxo-butanoic acid as a crystalline solid (4.2 g). A portion crystallized from diethyl ether/n-hexane had m.p. 159-160 °C. - e) 4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone.
A mixture of 4-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-methyl-4-oxo-butanoic acid (17.2 g), ethanol (356 ml) and hydrazine hydrate (85%, 55 ml) was stirred and heated at reflux. After 3 hours the reaction mixture was concentrated to about 100 ml under reduced pressure then poured into water (100 ml). The resultant solid was filtered and dried at 65 °C under vacuum to give crude pyridazinone as a white solid (15.25 g). The crude product was dissolved in hot methanol (1500 ml), filtered dust-free then concentrated and the resultant precipitate was filtered and dried to give 4,5-dihydro-6-(5,6-dimethoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone (14.6 g), m.p. 204-206 °C. - In an analogous manner as described in Example 1 were prepared:
4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl) -5-methyl-3(2H)-pyridazinone. m.p. 195-197 °C. 4,5-Dihydro-6-(6-methoxy-benzo{b}thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 210-212 °C.
4,5-Dihydro-6-(5-hydroxy-6-methoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. >275 °C. -
- a) 3-(5,6-Dimethoxy-benzo[b]thien-2-yl)-3-oxo-propanoic acid methyl ester.
A mixture of sodium hydride (60% dispersion in oil, 10.9 g) and dimethyl carbonate (18.7 ml) in dry tetrahydrofuran (210 ml) was stirred and heated at reflux under an atmosphere of nitrogen. A solution of 2-acetyl-5,6-dimethoxy-benzo[b]thiophene (21.0 g) in dry tetrahydrofuran (315 ml) was added dropwise over 30 min. Shortly after the addition of the benzothiophene solution had commenced potassium hydride (22.7% dispersion in oil) was added to initiate the reaction (sufficient to cause a permanent pink colour). When the evolution of gas had ceased (90 min.) the reaction mixture was cooled in an ice bath and treated with glacial acetic acid (34 ml). The resultant yellow solution was poured into ice-cold water (2 litre), stirred, and the yellow solid was filtered, washed with n-hexane and dried at 50 °C under vacuum to give 3-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-oxo-propanoic acid methyl ester (22.0 g). A portion crystallized from dichloromethane/diethyl ether had m.p. 129-130 °C. - b) 4-(5,6-Dimethoxy-benzo[b]thien-2-yl)-4-oxo-butanoic acid.
Sodium hydride (60% dispersion in oil, 1.37 g) in dry tetrahydrofuran (15 ml) was stirred at room temperature under an atmosphere of nitrogen and treated dropwise over 10 min. with a solution of 3-(5,6-dimethoxy-benzo[b]thien-2-yl)-3-oxo-propanoic acid methyl ester (5.0 g) in dry tetrahydrofuran (75 ml). After 30 min. ethylbromoacetate (4.0 ml) was added and the reaction mixture was stirred at room temperature for a further 45 min. and then warmed to 40 °C. After 2 hours the suspension was cooled, treated with glacial acetic acid (2 ml) then poured into water (400 ml). The mixture was extracted with diethyl ether (2 x 100 ml), the organic extracts were combined, washed with water (50 ml), dried (MgSO₄), filtered and evaporated to dryness. The residue was dissolved in ethanol (25 ml), 5M hydrochloric acid (50 ml) was added and then the solution was heated at reflux for 10 hours. The resultant white suspension was cooled to room temperature and treated dropwise with 10M potassium hydroxide (30 ml). The reaction mixture was then stirred and heated at reflux under an atmosphere of nitrogen. After 1 hour the solution was cooled, diluted with water (100 ml) and extracted with ethyl acetate (50 ml). The aqueous layer was separated, stirred and acidified with 5M hydrochloric acid (10 ml). The resultant precipitate was filtered off, washed with water and dried at 65 °C under vacuum to give 4-(5,6-dimethoxy-benzo[b]thien-2-yl)-4-oxo-butanoic acid as a pale yellow solid (4.68 g). A portion crystallized from dichloromethane/methanol had m.p. 177-178 °C. - c) 4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]thien-2-yl)-3(2H)-pyridazinone.
Using the procedure described in Example 1(e), 4-(5,6-dimethoxy-benzo[b]thien-2-yl)-4-oxo-butanoic acid was converted into 4,5-dihydro-6-(5,6-dimethoxy-benzo[b]-thien-2-yl)-3(2H)-pyridazinone, m.p. 254-256 °C. - In an analogous manner as described in Example 3 were prepared:
4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl)-3(2H)-pyridazinone. m.p. 188-190 °C. - A mixture of 4,5-dihydro-6-(5,6-dimethoxy-benzo[b]thien-2-yl)-3(2H)-pydridazinone and activated manganese dioxide (6.0 g) in dry dioxan (80 ml) and dry dimethylformamide (16 ml) was stirred and heated at reflux for 48 hours. Fresh manganese dioxide (6.0 g) was then added and the reflux was continued for a further 24 hours. The reaction mixture was then filtered through a dicalite pad and the filtrate was evaporated to dryness. The residue (1.27 g) was purified by chromatography through a column of fine silica using 3% v/v methanol/ dichloromethane as the eluant. The appropriate fractions were combined, evaporated and the product was crystallized from dichloromethane/methanol to give 6-(5,6-dimethoxy-benzo[b]thien-2-yl)-3(2H)-pyridazinone (0.41 g), m.p. >300 °C.
-
- a) 4-(5,6-Dimethoxy-benzo[b]furan-2-yl)-4-oxo-butanoic acid methyl ester.
To a stirred suspension of 4,5-dimethoxy-2-hydroxy-benzaldehyde (9.3 g) in dry ethanol (90 ml) under nitrogen was added slowly a solution of potassium hydroxide (3.14 g) in dry ethanol (60 ml). The resulting solution was stirred for 20 minutes, then 5-bromo-4-oxo-pentanoic acid methyl ester (10.65 g) was added slowly. The mixture was stirred for 24 hours, then diluted slowly with water (900 ml). The precipitated solid was filtered off, washed with water, dried under vacuum and crystallized from acetone-ether to give 4-(5,6-dimethoxy-benzo[b]furan-2-yl)-4-oxo-butanoic acid methyl ester (4.78 g).
A sample purified by column chromatography on silica, followed by crystallization from dichloromethane/methanol then acetone/ether had m.p. 140-142 °C. - b) 4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl)-3(2H)-pyridazinone.
To a stirred suspension of 4-(5,6-dimethoxy-benzo[b]furan-2-yl)-4-oxo-butanoic acid methyl ester (4.2 g) in ethanol (84 ml) was added water (2.1 ml), followed by hydrazine hydrate (13.4 ml). The mixture was heated to reflux for 2.3/4 hours, then cooled in cold water, diluted with water (250 ml) and acidified with 2M hydrochloric acid (150 ml). The solid was filtered off, washed with water, and dried. Purification of the crude product by column chromatography on silica and crystallization from dichloromethane/methanol gave 4,5-dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl-3(2H)-pyridazinone (2.87 g), m.p. 188-190 °C. - In an analogous manner as described in Example 6 was prepared:
4,5-Dihydro-6-(5,6-dimethoxy-benzo[b]furan-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 195-197 °C. - Boron tribromide (1.55 ml) was added to a stirred solution of 4,5-dihydro-6-(5,6-dimethoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone (1.14 g) in dichloromethane (200 ml). After 2 hours the orange solution was cooled in ice, and water (40 ml) was added. The dichloromethane was then evaporated off under reduced pressure and the residual suspension was filtered to give 4,5-dihydro-6-(5,6-dihydroxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone (0.97 g) as a yellow solid. Crystallisation from dichloromethane:methanol and diethylether gave 4,5-dihydro-6-(5,6-dihydroxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. >270 °C.
- In an analogous manner as described in Example 8 was prepared: 4,5-dihydro-6-(6-hydroxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 263-265 °C.
- A mixture of 4,5-dihydro-6-(5,6-dihydroxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone (1.59 g) and anhydrous potassium carbonate (1.69 g) in dimethyl formamide (18 ml) was stirred at room temperature for 10 mins. Iodoethane (0.92 ml) was then added and the reaction mixture was stirred for 16 hours. The resultant suspension was then poured into water (90 ml), the mixture was stirred, and the light yellow coloured precipitate was filtered off and dried at 75 °C under vacuum to give 4,5-dihydro-6-(5,6-diethoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone (1.65 g). Crystallization from dichloromethane: methanol and diethyl ether gave 4,5-dihydro-6-(5,6-diethoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone as a white solid (1.38 g), m.p. 170-171 °C.
- In an analogous manner as described in Example 9 were prepared:
4,5-Dihydro-6-(6-ethoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 236-239 °C.
4,5-Dihydro-6-(5-ethoxy-6-methoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone. m.p. 185-188 °C. - A mixture of 4,5-dihydro-6-(5-hydroxy-6-methoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone (1.0 g), anhydrous potassium carbonate (1.0 g) and 1-(3-chloropropyl)piperidine hydrochloride (0.72 g) in dimethyl formamide (12 ml) was stirred at room temperature for 3 days. The mixture was then warmed to 65°C and, after a further 2 hours, more anhydrous potassium carbonate (0.50 g) and 1-(3-chloropropyl)piperidine hydrochloride (0.36 g) were added. After a further 2 hours the reaction mixture was cooled to room temperature and poured into water (60 ml). The product, which precipitated as a gum, was isolated by decantation and then crystallized from ethyl acetate to give 4,5-dihydro-6-(6-methoxy-5-[3-(piperidin-1-yl)propyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone as a white solid (0.90 g), m.p. 198-200 °C.
- Conversion to hydrochloride salt: The free base (0.90 g) was suspended in methanol (50 ml) and the mixture was stirred and acidified to pH 1 using a solution of dry hydrochloric acid in methanol. The free-base dissolved and the resultant solution was filtered dust-free, concentrated and then crystallized from methanol and diethyl ether to give 4,5-dihydro-6-(6-methoxy-5-[3-(piperidin-1-yl)propyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride as a white solid (0.91 g). m.p. >235 °C (dec.).
- In an analogous manner as described in Example 12, were prepared:
4,5-Dihydro-6-(6-methoxy-5-[2-(piperidin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride. m.p. 192-200 °C
4,5-Dihydro-6-(5-[2-(piperidin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride. m.p. 245-248 °C
4,5-Dihydro-6-(6-[2-(piperidin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride. m.p. 247-250 °C
4,5-Dihydro-6-(6-methoxy-5-[2-methyl-3-(piperidin-1-yl)propyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(6-methoxy-5-[2-hydroxy-3-(piperidin-1-yl)propyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(6-methoxy-5-[2-(4-methyl-piperazin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(6-methoxy-5-[2-(piperazin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(6-methoxy-5-[2-(morpholin-4-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(5-[2-(imizadol-1-yl)ethyloxy-6-methoxy]-benzo[b]thien-2-yl)-5-methyl-3-(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(6-methoxy-5-[2-(dimethylamino)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3-(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(6-methoxy-5-[2-(piperidin-1-yl)ethyloxy]-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
4,5-Dihydro-6-(5-[2-diethylaminoethyloxy]-6-methoxy-benzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone hydrochloride.
Claims (7)
- Pyridazinone derivatives of the general formula I:R¹ represents one to four substituents, which may be the same or different and are selected from OH, unsubstituted or C1-C4 alkyl substituted amino, C1-C4 halogen substituted alkyl, O-ALK-NR⁴R⁵, C1-C4 alkoxy, whereby two substituents taken together may also represent a methylenedioxy group ;R² and R³ represent independently H or C1-C4 alkyl;R⁴ and R⁵ represent independently H or C1-C4 alkyl, or form together with the nitrogen a 5- or 6- membered ring;ALK represents a branched or unbranched alkylene group with 2-6 C atoms, which optionally may be substituted with hydroxy or halogen;X represents S or O;
the dotted line represents an optional bond;
and their pharmaceutically acceptable salts. - Compounds according to claim 1, wherein R¹ represents OH, C1-C4 alkoxy or O-ALK-NR⁴R⁵, R² and R³ represent H or CH₃ and there are 2, 3 or 4 substituents R¹, which may be the same or different.
- Compounds according to claim 1, wherein R¹ represents OH, OCH₃, OC₂H₅, 2-(piperidin-1-yl)ethyloxy or 2-(piperidin-1-yl)propyloxy, R² represents H, R³ represents CH₃, X represents S, there are 2 or 3 substituents R¹ which may be the same or different and the optional bond is not present.
- Pharmaceutical preparation containing a compound according to claim 1 as the active principle in admixture with a pharmaceutically acceptable carrier.
- Process of analogy for the preparation of a compound according to claim 1, wherein a ketoacid of formula III
- Use of compounds according to claim 1 for the preparation of a medicament with pulmonary vasodilator, bronchodilator, systemic vasodilator, blood platelet aggregation inhibiting and cardiotonic activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP88306295 | 1988-07-11 | ||
EP88306295 | 1988-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0350990A1 EP0350990A1 (en) | 1990-01-17 |
EP0350990B1 true EP0350990B1 (en) | 1995-09-20 |
Family
ID=8200131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89201716A Expired - Lifetime EP0350990B1 (en) | 1988-07-11 | 1989-06-29 | Pyridazinone derivatives |
Country Status (16)
Country | Link |
---|---|
US (1) | US4952571A (en) |
EP (1) | EP0350990B1 (en) |
JP (1) | JPH0285281A (en) |
KR (1) | KR900001691A (en) |
AT (1) | ATE128135T1 (en) |
AU (1) | AU617489B2 (en) |
CA (1) | CA1308413C (en) |
DE (1) | DE68924308T2 (en) |
DK (1) | DK340889A (en) |
ES (1) | ES2080064T3 (en) |
FI (1) | FI97295C (en) |
GR (1) | GR3018356T3 (en) |
IE (1) | IE68680B1 (en) |
NZ (1) | NZ229876A (en) |
PT (1) | PT91117B (en) |
ZA (1) | ZA895087B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL94394A (en) * | 1989-05-17 | 1994-10-21 | Nissan Chemical Ind Ltd | Pyridazinone derivatives, process for their preparation and compositions for controlling and/or preventing insects, acarides, nematodes and molluscs |
KR100226053B1 (en) * | 1996-06-18 | 1999-10-15 | 권태웅 | Video printer interface module for factory control system |
US6276721B1 (en) * | 2000-03-14 | 2001-08-21 | Simula, Inc. | Pivoting seat belt upper anchor point attachment |
FR2829977B1 (en) * | 2001-09-24 | 2003-12-12 | Valeo Vision | LIGHTING OR SIGNALING PROJECTOR WITH INTEGRATED CONTROLLER FOR VEHICLE AND LIGHTING OR SIGNALING SYSTEM PROVIDED WITH AT LEAST ONE SUCH PROJECTOR |
ES2893532T3 (en) * | 2016-10-04 | 2022-02-09 | Merck Sharp & Dohme | Benzo[b]thiophene compounds as STING agonists |
WO2019027857A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT |
AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
EP3774765A4 (en) | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
KR20200139203A (en) * | 2018-04-03 | 2020-12-11 | 머크 샤프 앤드 돔 코포레이션 | Benzothiophene and related compounds as STING agonists |
CN113861161A (en) * | 2020-06-30 | 2021-12-31 | 上海海和药物研究开发股份有限公司 | Aryl aromatic heterocyclic derivative and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8101067A1 (en) * | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | Benzimidazoles, their preparation and pharmaceutical compositions containing them. |
US4225711A (en) * | 1978-10-02 | 1980-09-30 | Schering Corporation | Substituted 2-[(methylsulfinyl)acetyl]-3-heterocyclicindoles and their use as immunosuppressants |
DE3129447A1 (en) * | 1981-07-25 | 1983-02-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | "NEW BENZTRIAZOLES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS" |
CA1199027A (en) * | 1981-11-12 | 1986-01-07 | Stuart D. Mills | Heterocyclic derivatives of pyridazinone, thiadiazinone, oxadiazinone and triazinone |
US4666902A (en) * | 1983-06-20 | 1987-05-19 | Cassella Aktiengesellschaft | Tetrahydropyridazinone derivatives, processes for their preparation and their use |
US4647564A (en) * | 1984-05-14 | 1987-03-03 | Eli Lilly And Company | Inotropic agents |
DE3511110A1 (en) * | 1985-03-27 | 1986-10-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW PYRIDAZINONE, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3631085A1 (en) * | 1986-09-12 | 1988-03-24 | Boehringer Mannheim Gmbh | HETEROCYCLICALLY SUBSTITUTED INDOLINONES, PROCESS FOR THEIR PRODUCTION, MEDICINAL PRODUCTS AND INTERMEDIATE PRODUCTS |
-
1989
- 1989-06-29 AT AT89201716T patent/ATE128135T1/en not_active IP Right Cessation
- 1989-06-29 DE DE68924308T patent/DE68924308T2/en not_active Expired - Fee Related
- 1989-06-29 ES ES89201716T patent/ES2080064T3/en not_active Expired - Lifetime
- 1989-06-29 EP EP89201716A patent/EP0350990B1/en not_active Expired - Lifetime
- 1989-07-03 IE IE214889A patent/IE68680B1/en not_active IP Right Cessation
- 1989-07-04 ZA ZA895087A patent/ZA895087B/en unknown
- 1989-07-07 NZ NZ229876A patent/NZ229876A/en unknown
- 1989-07-07 AU AU37967/89A patent/AU617489B2/en not_active Ceased
- 1989-07-10 DK DK340889A patent/DK340889A/en not_active Application Discontinuation
- 1989-07-10 KR KR1019890009773A patent/KR900001691A/en not_active Application Discontinuation
- 1989-07-10 CA CA000605216A patent/CA1308413C/en not_active Expired - Fee Related
- 1989-07-10 PT PT91117A patent/PT91117B/en not_active IP Right Cessation
- 1989-07-10 FI FI893345A patent/FI97295C/en not_active IP Right Cessation
- 1989-07-10 JP JP1177872A patent/JPH0285281A/en active Pending
- 1989-07-11 US US07/378,342 patent/US4952571A/en not_active Expired - Fee Related
-
1995
- 1995-12-11 GR GR950403477T patent/GR3018356T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE68924308D1 (en) | 1995-10-26 |
ZA895087B (en) | 1990-03-28 |
IE68680B1 (en) | 1996-07-10 |
DK340889A (en) | 1990-01-12 |
JPH0285281A (en) | 1990-03-26 |
CA1308413C (en) | 1992-10-06 |
PT91117A (en) | 1990-02-08 |
NZ229876A (en) | 1991-03-26 |
PT91117B (en) | 1995-07-06 |
AU617489B2 (en) | 1991-11-28 |
EP0350990A1 (en) | 1990-01-17 |
FI893345A0 (en) | 1989-07-10 |
GR3018356T3 (en) | 1996-03-31 |
FI97295C (en) | 1996-11-25 |
US4952571A (en) | 1990-08-28 |
DE68924308T2 (en) | 1996-04-04 |
ES2080064T3 (en) | 1996-02-01 |
FI893345A (en) | 1990-01-12 |
AU3796789A (en) | 1990-01-11 |
ATE128135T1 (en) | 1995-10-15 |
FI97295B (en) | 1996-08-15 |
DK340889D0 (en) | 1989-07-10 |
KR900001691A (en) | 1990-02-27 |
IE892148L (en) | 1990-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4665206A (en) | Benzothiophene derivatives | |
SU1232144A3 (en) | Method of producing carbostyrene derivatives | |
US5231101A (en) | Benzo[5,6]cyclohepta[1,2-B]pyridine derivatives and antiallergic agents comprising same | |
CA1041095A (en) | Benzimidazoles | |
JP2852659B2 (en) | Piperazine derivatives and their salts | |
GB2071094A (en) | Carbostyril derivatives processes for their production andpharmaceutical composition containing them | |
PL175556B1 (en) | Derivatives of benzopyrane, benzothiopyrane and benzofurane as well as method of obtaining them | |
NZ199254A (en) | Pyrimidone derivatives and pharmaceutical compositions | |
EP0350990B1 (en) | Pyridazinone derivatives | |
CA1241000A (en) | 4h-1-benzopyran-4-ones and their sulfur containing analogs | |
EP0325755A1 (en) | Tricyclic compounds | |
EP0070518A2 (en) | Imidazoquinoxaline compounds | |
JPH07116155B2 (en) | Anti-inflammatory 4-aminophenol derivative | |
US4710506A (en) | Antihypertensive thienopyridines | |
SK288126B6 (en) | Benzofuran and benzothiophene derivatives, process for their preparation and pharmaceutical or veterinary preparations containing them. | |
US4555509A (en) | Anti-hypertensive benzo[b]pyran-3-ols | |
KR19980064040A (en) | Pyridine Derivatives, Methods of Making Pyridine Derivatives and Intermediates therefor | |
HUT58323A (en) | Process for producing new chromane derivatives and pharmaceutical compositions containing them | |
JPS6140674B2 (en) | ||
AU705959B2 (en) | Endothelin receptor antagonists | |
HUT61538A (en) | Process for producing new 2-amino-5-cyano-1,4-dihydropyridine derivatives and pharmaceutical compositions comprising same | |
US4373104A (en) | Sulfur-containing isoquinoline derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
JPH04300880A (en) | Chroman derivative | |
GB2047698A (en) | 6-substituted pyranone compounds and their use as pharmaceuticals | |
US3798225A (en) | 3(2h)-isoquinolones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19900710 |
|
17Q | First examination report despatched |
Effective date: 19920622 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AKZO NOBEL N.V. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 128135 Country of ref document: AT Date of ref document: 19951015 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 68924308 Country of ref document: DE Date of ref document: 19951026 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: JACOBACCI & PERANI S.P.A. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2080064 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3018356 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19970513 Year of fee payment: 9 Ref country code: FR Payment date: 19970513 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19970521 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19970522 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19970523 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19970527 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 19970530 Year of fee payment: 9 Ref country code: DE Payment date: 19970530 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19970617 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19970625 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980629 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980630 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980630 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980630 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980630 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980630 |
|
BERE | Be: lapsed |
Owner name: AKZO NOBEL N.V. Effective date: 19980630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990101 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19980629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990226 |
|
EUG | Se: european patent has lapsed |
Ref document number: 89201716.1 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19990101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990401 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20000403 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050629 |